Abstract
Covalent conjugation of anticancer drugs to targeting carriers (e.g., antibodies or small molecules) capable of selectively binding to tumor-specific antigens, is emerging as a successful strategy to overcome the drawbacks of traditional chemotherapy. Due to its overexpression on blood vessels of human tumors, αvβ3 integrin is one of the most studied receptors of tumor-targeted therapeutics: several peptides and peptidomimetics, bearing the RGD (Arg-Gly-Asp) recognition sequence, have been developed as integrin ligands and linked to different anticancer drugs. The resulting integrin- targeted small molecule-drug conjugates (SMDCs) are able to release the cytotoxic agents upon cleavage of a linker under specific conditions (i.e., hydrolysis, enzymatic action or reduction). Despite the significant efforts made in this field, αvβ3 integrin-targeted SMDCs are still far from the clinic. In this review, we survey this approach with a special focus on the different linkers employed and the reported biological activities in vitro and in vivo.
Keywords: Anticancer Prodrugs, Drug Targeting, Integrins, Peptidomimetics, RGD, Small Molecule-Drug Conjugates.
Current Topics in Medicinal Chemistry
Title:αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology
Volume: 16 Issue: 3
Author(s): Alberto Dal Corso, Luca Pignataro, Laura Belvisi and Cesare Gennari
Affiliation:
Keywords: Anticancer Prodrugs, Drug Targeting, Integrins, Peptidomimetics, RGD, Small Molecule-Drug Conjugates.
Abstract: Covalent conjugation of anticancer drugs to targeting carriers (e.g., antibodies or small molecules) capable of selectively binding to tumor-specific antigens, is emerging as a successful strategy to overcome the drawbacks of traditional chemotherapy. Due to its overexpression on blood vessels of human tumors, αvβ3 integrin is one of the most studied receptors of tumor-targeted therapeutics: several peptides and peptidomimetics, bearing the RGD (Arg-Gly-Asp) recognition sequence, have been developed as integrin ligands and linked to different anticancer drugs. The resulting integrin- targeted small molecule-drug conjugates (SMDCs) are able to release the cytotoxic agents upon cleavage of a linker under specific conditions (i.e., hydrolysis, enzymatic action or reduction). Despite the significant efforts made in this field, αvβ3 integrin-targeted SMDCs are still far from the clinic. In this review, we survey this approach with a special focus on the different linkers employed and the reported biological activities in vitro and in vivo.
Export Options
About this article
Cite this article as:
Dal Corso Alberto, Pignataro Luca, Belvisi Laura and Gennari Cesare, αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology, Current Topics in Medicinal Chemistry 2016; 16 (3) . https://dx.doi.org/10.2174/1568026615666150701114343
DOI https://dx.doi.org/10.2174/1568026615666150701114343 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
Addressing the Most Common Causes of Death with Niacin/NAD and Inositol Polyphosphates
The most common causes of death in the world are cardiovascular disease (CVD) and cancer. These are perhaps best addressed by reducing lipodystrophy and blockages with niacin and inositol polyphosphates (e.g., IP6+inositol) respectively when addressing CVD. Niacin serves as a vitamin by virtue of its role as a skeletal precursor ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Functional PLGA NPs for Oral Drug Delivery: Recent Strategies and Developments
Mini-Reviews in Medicinal Chemistry Erlotinib in Glioblastoma - Lost in Translation?
Anti-Cancer Agents in Medicinal Chemistry Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants
Current Neuropharmacology The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism
Current Alzheimer Research The Effects of Colchicum baytopiorum on Regulatory Genes of Apoptotic and Autophagic Cell Death in HeLa Cells
Current Pharmaceutical Biotechnology Subject Index to Volume 3
Current Gene Therapy The Design of Vectors for RNAi Delivery System
Current Pharmaceutical Design Non-Invasive Cell Tracking in Cancer and Cancer Therapy
Current Topics in Medicinal Chemistry Application of Glutathione as Anti-Oxidative and Anti-Aging Drugs
Current Drug Metabolism Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Current Constructs and Targets in Clinical Development for Antibody- Based Cancer Therapy
Current Drug Targets DNA Demethylation: Where Genetics Meets Epigenetics
Current Pharmaceutical Design Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Current Molecular Medicine Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy
Current Pharmaceutical Design Dendritic Cells and their Receptors in Antitumor Immune Response
Current Molecular Medicine Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry